Trials / Withdrawn
WithdrawnNCT05808881
Clinical Outcomes From Nalmefene
Clinical Outcomes From Injectable Nalmefene in the Emergency Department (COINED)
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Purdue Pharma LP · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the effectiveness of nalmefene relative to naloxone for the reversal of opioid intoxication in emergency department (ED) settings.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nalmefene Hydrochloride Injection | for intravenous/intramuscular/subcutaneous (IV/IM/SC) administration |
| DRUG | Naloxone Hydrochloride Injection | for intravenous/intramuscular/subcutaneous (IV/IM/SC) administration |
Timeline
- Start date
- 2023-06-01
- Primary completion
- 2024-05-01
- Completion
- 2024-05-01
- First posted
- 2023-04-12
- Last updated
- 2023-07-12
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05808881. Inclusion in this directory is not an endorsement.